Periodontal repair in dogs: effect of recombinant human transforming growth factor-beta1 on guided tissue regeneration.
This study evaluated alveolar bone and cementum regeneration following surgical implantation of recombinant human transforming growth factor-beta1 (rhTGF-beta1) in conjunction with guided tissue regeneration (GTR). Supraalveolar, critical size, periodontal defects were surgically created around the 3rd and 4th mandibular premolar teeth in right and left jaw quadrants in 5 beagle dogs. Alternate jaw quadrants in consecutive animals received rhTGF-beta1, in a CaCO3/hydroxyethyl starch carrier with GTR, or carrier with GTR alone (control). 20 microg of rhTGF-beta1 in buffer solution was incorporated into approximately 0.8 ml of carrier for each defect scheduled to receive rhTGF-beta1. Animals were sacrificed at week 4 postsurgery and tissue blocks were harvested and processed for histometric analysis. Clinical healing was generally uneventful. Minor membrane exposures were observed. Defects with membrane exposure displayed an inflammatory infiltrate underneath the membrane. Bone regeneration of trabecular nature, apparent in all animals, was generally limited to the very apical aspect of the defects. Cementum regeneration was limited without obvious differences between experimental conditions. Comparing rhTGF-beta1, to control defects, statistically significant differences were found for area (1.8+/-0.4 and 1.3+/-0.6 mm2, respectively; p<0.05) and density (0.3+/-0.1 and 0.2+/-0.03, respectively; p<0.05) of alveolar bone regeneration. Observed differences are small and represent a clinically insignificant potential for enhanced regeneration in this preclinical model. Within the limitations of study, it may be concluded that rhTGF-beta1 has a restricted potential to enhance alveolar bone regeneration in conjunction with GTR.
Wikesjö
U M
UM
Loma Linda University, CA, USA. uwikesjo@genetics.com
Razi
S S
SS
Sigurdsson
T J
TJ
Tatakis
D N
DN
Lee
M B
MB
Ongpipattanakul
B
B
Nguyen
T
T
Hardwick
R
R
D016301:Alveolar Bone Loss / Q000601:surgery; D000539:Alveolar Process / Q000473:pathology; D000818:Animals; D001641:Bicuspid; D001861:Bone Regeneration; D002119:Calcium Carbonate; D003739:Dental Cementum / Q000473:pathology; D004285:Dogs; D004337:Drug Carriers; D017823:Furcation Defects / Q000601:surgery; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D008567:Membranes, Artificial; D010510:Periodontal Diseases / Q000601:surgery; D011138:Polytetrafluoroethylene; D011994:Recombinant Proteins; D012038:Regeneration; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000627:therapeutic use*
D004337:Drug Carriers; D006895:Hydroxyethyl Starch Derivatives; D008567:Membranes, Artificial; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D011138:Polytetrafluoroethylene; D002119:Calcium Carbonate